Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial

Schmier, Jordana K.; Li, Su; King, James C.; Nichol, Kristin L.; Mahadevia, Parthiv J.

doi:10.1377/hlthaff.27.2.w96

Cited by 52 publications

(78 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14 However, unlike other studies, our analysis included the costs of fringe benefits, overhead, and staff time for planning. Our estimates also included the value of school staff time, which was critical to the collection of consents and managing the day of vaccination.…”

Section: Discussionmentioning

confidence: 99%

Cost Comparison of 2 Mass Vaccination Campaigns Against Influenza A H1N1 in New York City

Kansagra

McGinty²,

Morgenthau³

et al. 2012

Am J Public Health

View full text Add to dashboard Cite

Objectives. We estimated and compared total costs and costs per dose administered for 2 influenza A 2009 monovalent vaccine campaigns in New York City: an elementary school-located campaign targeting enrolled children aged 4 years and older, and a community-based points-of-dispensing campaign for anyone aged 4 years and older. Methods. We determined costs from invoices or we estimated costs. We obtained vaccination data from the Citywide Immunization Registry and reports from the community points of dispensing. Results. The school campaign delivered approximately 202,089 vaccines for $17.9 million and $88 per dose. The community campaign delivered 49,986 vaccines for $7.6 million and $151 per dose. At projected capacity, the school campaign could have delivered 371,827 doses at $53 each or $13 each when we excluded the value of in-kind resources. The community points of dispensing could have administered 174,000 doses at $51 each or $24 each when we excluded the value of in-kind resources. Conclusions. The school campaign delivered vaccines at a lower cost per dose than did the community campaign. Had demand been higher, both campaigns may have delivered vaccine at lower, more comparable cost per dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost Comparison of 2 Mass Vaccination Campaigns Against Influenza A H1N1 in New York City

Kansagra

McGinty²,

Morgenthau³

et al. 2012

Am J Public Health

View full text Add to dashboard Cite

show abstract

“…Based on data from a large controlled clinical trial, Schmier et al estimated the averted medical expenditure to be $117.45 (adjusted to 2009 dollars) for all members in a household during an influenza season [23]. This averted medical expenditure represents the difference in direct influenza costs between intervention and control schools.…”

Section: Methodsmentioning

confidence: 99%

Cost effectiveness analysis of elementary school-located vaccination against influenza—Results from a randomized controlled trial

Yoo

Humiston

Szilâgyi

et al. 2013

Vaccine

View full text Add to dashboard Cite

School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009–2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n=9,027 children) with standard of care (no SLV-I) in 11 control schools (n=4,534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to “no vaccination”. Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs.

show abstract

“…A number of studies assess the use of LAIV as a cost-saving or cost-effective intervention [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]. However, not all studies reach consistent results.…”

Section: Answering the Research Questionsmentioning

confidence: 99%

Vaccination of children with a live-attenuated, intranasal influenza vaccine – analysis and evaluation through a Health Technology Assessment

Andersohn

Bornemann

Damm

et al. 2014

GMS Health Technology Assessment; 10:Doc03; ISSN 1861-8863

View full text Add to dashboard Cite

Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial

Cited by 52 publications

References 7 publications

Cost Comparison of 2 Mass Vaccination Campaigns Against Influenza A H1N1 in New York City

Cost Comparison of 2 Mass Vaccination Campaigns Against Influenza A H1N1 in New York City

Cost effectiveness analysis of elementary school-located vaccination against influenza—Results from a randomized controlled trial

Vaccination of children with a live-attenuated, intranasal influenza vaccine – analysis and evaluation through a Health Technology Assessment

Contact Info

Product

Resources

About